Division of Interventional Radiology, Department of Radiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Acta Radiol. 2022 Jan;63(1):59-66. doi: 10.1177/02841851211005163. Epub 2021 Mar 27.
Endovascular treatment is a first-line treatment for upper thoracic central vein obstruction (CVO). Few studies using bare venous stents (BVS) in CVO have been conducted.
To evaluate the treatment performance of upper thoracic central vein stenosis between BVS and conventional bare stent (CBS) in hemodialysis patients.
Hemodialysis patients with upper thoracic central vein obstruction who underwent endovascular treatment at the interventional unit of our institution from 1 January 2008 to 31 December 2018 were enrolled in the present study. CBS was used to treat central vein obstruction in 43 patients and BVS in 34 patients. We compared the primary patency rates and complications between the two stent types. values < 0.05 were considered statistically significant.
The patient demographic data between the CBS and BVS groups were similar. The characteristics of the lesions, procedures, and complications were not significantly different between the two groups ( > 0.05). There were no statistically significant differences of primary patency rates at three and six months between the BVS and CBS groups (94.1% vs. 86.0% and 73.5% vs. 58.1%, respectively; > 0.05). The primary patency rate at 12 months in the BVS group was significantly higher than that in the CBS group (61.8% vs. 32.6%; = 0.008).
Endovascular treatment of central vein obstruction with BVS provided a higher primary patency rate at 12 months than CBS.
血管内治疗是治疗上胸段中心静脉阻塞（CVO）的一线治疗方法。很少有研究使用裸静脉支架（BVS）治疗 CVO。
评估 BVS 和传统裸支架（CBS）在上胸段中心静脉狭窄治疗中的疗效。
本研究纳入了 2008 年 1 月 1 日至 2018 年 12 月 31 日在我院介入科接受血管内治疗的上胸段中心静脉阻塞的血液透析患者。43 例患者采用 CBS 治疗中心静脉阻塞，34 例患者采用 BVS 治疗。比较两种支架类型的初始通畅率和并发症。 值<0.05 为差异有统计学意义。
CBS 组和 BVS 组患者的人口统计学数据相似。两组患者的病变特征、手术过程和并发症无明显差异（ >0.05）。BVS 组和 CBS 组在 3 个月和 6 个月的初始通畅率无统计学差异（94.1%比 86.0%和 73.5%比 58.1%； >0.05）。BVS 组 12 个月的初始通畅率明显高于 CBS 组（61.8%比 32.6%； =0.008）。
与 CBS 相比，BVS 治疗中心静脉阻塞的初始通畅率在 12 个月时更高。
